## DVA: DaVita Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.16 indicates fundamental undervaluation. Quality metrics strong (ROE 62%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($115.91)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. 3 Takeaways From DaVita CEO Javier Rodriguez on the Future of Health Technology**
- Source: CSRwire | 20251212T164700 | Bullish | Relevance: 100%
- DaVita CEO Javier Rodriguez emphasizes a "revolution" in health technology, focusing on three key areas. He highlights how the consumerization of healthcare can improve equitable access, the potential of technology to enhance the care experience for both patients and clinicians, and the critical role of interoperability in creating a seamless, positive healthcare journey. These principles aim to transform kidney care and strengthen the broader healthcare ecosystem.

**2. Davita Inc. Appoints Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, Effective December 11, 2025**
- Source: marketscreener.com | 20251211T150813 | Bullish | Relevance: 100%
- DaVita Inc. (NYSE: DVA) has announced the appointments of Stephanie Hendrickson as Chief People Officer and Steve Phillips as Chief Strategy Officer, effective December 11, 2025. Hendrickson, who joined DaVita in 2013, will focus on strengthening teams, while Phillips will expand his role to oversee DaVita Venture Group and corporate strategy. These appointments highlight DaVita's commitment to visionary leadership and driving innovation in healthcare to improve patient outcomes and foster a thriving culture.

**3. UBS reiterates Buy rating on DaVita stock, maintains $186 price target**
- Source: Investing.com UK | 20251215T152010 | Somewhat-Bullish | Relevance: 100%
- UBS has re-affirmed its Buy rating for DaVita (NYSE:DVA) stock, setting a price target of $186.00, which suggests a 53% upside from its current trading price. The firm cites DaVitaâ€™s solid financial health and long-term adjusted operating income growth expectations of 3-7%, despite a recent Q3 2025 earnings per share and revenue miss. UBS also noted consistent growth frameworks and anticipated breakeven for DaVita's Integrated Kidney Care segment in 2026.

**4. Is DaVita Stock Underperforming the Dow?**
- Source: Markets Financial Content | 20251215T140500 | Bearish | Relevance: 100%
- DaVita Inc. (DVA), a mid-cap company providing kidney dialysis services, has experienced a significant underperformance compared to the Dow Jones Industrials Average ($DOWI). Its stock has decreased by 32.4% from its 52-week high, dropped 8.9% in the last three months, and declined 21.2% over the past year, while the DOWI has seen gains. Analysts are cautious, rating DVA as a "Hold" with a modest price target premium, particularly after a disappointing Q3 2025 due to higher costs, lower volumes, and a ransomware attack.

**5. Neuberger Berman Group LLC Buys 128,871 Shares of DaVita Inc. $DVA**
- Source: MarketBeat | 20251214T140729 | Somewhat-Bearish | Relevance: 100%
- Neuberger Berman Group LLC significantly increased its stake in DaVita Inc. by 197.2% in Q2, acquiring 128,871 shares, bringing its total to 194,235 shares valued at $27.67 million. Other institutional investors also boosted their positions, resulting in institutional ownership of 90.12%. Despite this, DaVita missed Q3 EPS estimates, offered cautious FY2025 guidance, and holds a "Reduce" consensus analyst rating with a $148 price target.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 4 ($55.95M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 69.6% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 7 |

**Top Holders:**
- Berkshire Hathaway, : 45.6% (-4.8%)
- Vanguard Group Inc: 6.0% (-10.9%)
- Blackrock Inc.: 5.1% (-13.1%)
- State Street Corpora: 2.6% (-12.4%)
- Invesco Ltd.: 2.4% (+2.0%)

### Key Risks

1. Heavy insider selling: $56M sold (4 transactions in 90 days).
2. High short interest (21.2%, 6.2 days to cover): squeeze risk or crowded bearish bet.
3. Long-term trend broken: trading 10.8% below SMA200.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +5.7% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.16 suggests fair value with growth premium. Forward P/E 9.5x attractive for 19% earnings growth. Quality metrics strong (ROE 62%). Insider selling cluster ($56.0M in 90 days), potential headwind. Institutional flow bearish (7 selling vs 3 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $8.7B |
| Beta | 0.99 |
| 52W Range | $113.97 - $179.60 |
| Short Interest | 21.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.16 |
| Forward P/E | 9.5 |
| Current P/E | 11.4 |
| YoY Growth | 19.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -3.8% to 1.9% (+5.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 2.1pp (needs >4.0% for momentum thesis). MRS_5 at 3.5% confirms short-term momentum alignment. Below SMA200 (0.89x), long-term trend not supportive. MACD histogram positive (0.53), confirming momentum. RSI neutral at 54. OFD pattern: +SBL (Volatile).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 1.90% (CS: 53) | Neutral |
| RSI_14 | 53.9 | Neutral |
| MACD Histogram | 0.53 | Bullish |
| vs SMA20 | 1.023x | Above |
| vs SMA50 | 0.990x | Below |
| vs SMA200 | 0.892x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $121.35
- **Stop Loss:** $115.91 (4.5% risk)
- **Target:** $132.23 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 183
- **Position Value:** $22,207.05
- **Portfolio %:** 22.21%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX remains calm at 15.74 while breadth shows modest participation at 54%, suggesting selective positioning. FOMC meeting in 4 days creates near-term uncertainty but no systemic stress evident.*

### Earnings

**Next:** 2026-02-12 (Est: $3.19)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.17 | $2.51 | -20.9% |
| 2025Q2 | $2.75 | $2.95 | +7.3% |
| 2025Q1 | $2.02 | $2.00 | -0.9% |
| 2024Q4 | $2.13 | $2.24 | +5.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*